跳到正文
原文
BioPharma Dive· Jonathan Gardner·· 2026-10-19AI 评分59

Merck KGaA以13亿美元收购Silence Therapeutics,获得真性红细胞增多症在研RNAi药物

Merck KGaA bets on RNAi with $1.3B Silence buyout

AI 导读

Merck KGaA于2026年10月19日宣布以13亿美元收购英国Silence Therapeutics,获得真性红细胞增多症在研RNAi药物divesiran。交易对价为每股20美元现金,溢价130%,预计2027年第一季度完成。divesiran在II期试验中显著减少患者采血次数,若获批将与Mimrylo和Jakafi竞争,但还需开展III期项目。

正文

An article from site logo

Dive Brief

The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.

Published Oct. 19, 2026

Jonathan Gardner's headshot

Exterior building picture of the Merck KGaA Life Science site in Burlington, U.S.

Merck KGaA announced it was acquiring Silence Therapeutics for more than $1 billion on Oct. 19, 2026. Courtesy of Merck KGaA

Dive Brief:

  • Merck KGaA is buying into RNA medicine, announcing Monday the $1.3 billion buyout of UK-based Silence Therapeutics to gain control of a medicine that has delivered positive Phase 2 data in the rare blood disorder polycythemia vera.
  • Per deal terms, the bigger drugmaker will pay $20 in cash for every U.S.-listed Silence share. The deal thereby carries a 130% premium, the second highest this year among the bigger-ticket transactions tracked by BioPharma Dive. Key shareholders representing 14% of Silence’s voting power have already agreed to the deal, which German Merck expects to close in the first quarter of 2027.
  • Merck KGaA will take ownership of a so-called short-interfering RNA therapy that, if approved, will compete with a Takeda Pharmaceutical and Protagonist Therapeutics medicine named Mimrylo, along with older treatments like Incyte’s Jakafi. Reviewing Phase 2 data, Wall Street analysts concluded that Silence’s drug, “divesiran,” could be “best in class” and has the potential to match Mimrylo’s forecasted blockbuster sales.

Dive Insight:

Merck KGaA CEO Kai Beckmann described the transaction as part of an effort to “transform our pipeline toward areas of high specialization and unmet medical need, with an ongoing commitment to external innovation,” following on a buyout of Springworks Therapeutics last year that brought in drugs for two rare tumor disorders.

In that case, Merck KGaA obtained already approved products. With Silence, it will need to invest in a Phase 3 program, although the big drugmaker has more resources to complete the program than the $72 million in cash and equivalents that Silence had in hand as of June 30.

After analyzing that Phase 2 data, analysts from Cantor Fitzgerald suggested that, because of its strong efficacy, divesiran might not need the nearly 300 patients that Takeda and Protagonist enrolled in their Phase 3 Mimrylo trial. They also argued that Silence's drug “meaningfully exceeded the efficacy shown by” Mimrylo.

“This deal takes the execution risk off the table in an increasingly competitive space and delivers near-term shareholder value from what appears to be a competitive bid process,” William Blair analyst Myles Minter, who covers Silence, wrote in a client note.

In polycythemia vera, a faulty gene stimulates the bone marrow to make too many red blood cells, increasing the risk of dangerous blood clots. The disease can also lead to an enlarged spleen, ulcers and gout. Treatment often consists of blood withdrawals, and if those don’t work well enough, patients can receive drugs like Jakafi, hydroxyurea, busulfan or a type of interferon.

Mimrylo and divesiran both work by increasing levels of a hormone called hepcidin, which suppresses iron metabolism. Divesiran does so by silencing a gene called TMPRSS6, which is being targeted by a similar drug Agios Pharmaceuticals is developing.

In mid-stage testing, divesiran was able to significantly reduce the number of blood draws in people who got it compared to those who got a placebo. It also reduced red blood cell levels below a threshold triggering the need for blood draws in significantly more people who got it, compared to those in the control arm.

来源:BioPharma Dive · biopharmadive.com